CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 17, 2026 /PRNewswire/ — Harbour BioMed (the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks

